PFE
PFIZER INC
NYSE · Healthcare · Drug Manufacturers - General · US
$30.42
+1.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 63.6B | 62.6B | 63.6B | 59.6B | 101.2B |
| Cost of Revenue | 16.9B | 16.1B | 17.9B | 25.0B | 34.3B |
| Gross Profit | 46.7B | 46.5B | 45.8B | 34.6B | 66.8B |
| Operating Expenses | |||||
| R&D Expense | 11.5B | 10.4B | 10.8B | 10.7B | 11.4B |
| SG&A Expense | 13.8B | 13.8B | 14.7B | 14.8B | 13.7B |
| General & Admin Expense | 3.3B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 6.2B | 4.9B | 5.3B | 4.7B | 3.6B |
| Total Operating Expenses | 31.5B | 29.1B | 30.8B | 30.2B | 28.7B |
| Cost and Expenses | 48.5B | 45.2B | 48.7B | 55.1B | 63.1B |
| Operating Income (EBIT) | 15.2B | 17.4B | 14.9B | 4.4B | 38.1B |
| Non-Operating | |||||
| Interest Income | 502.0M | 603.0M | 545.0M | 1.6B | 251.0M |
| Interest Expense | 2.7B | 2.7B | 3.1B | 2.2B | 1.2B |
| Net Interest Income | (2.2B) | (2.1B) | (2.5B) | (585.0M) | (987.0M) |
| Other Non-Op Income/Expense | (10.9B) | (9.9B) | (6.9B) | (3.4B) | (3.4B) |
| Non-Operating Income (excl Interest) | 8.2B | 7.2B | 3.8B | 1.1B | 2.1B |
| EBT (Pre-Tax Income) | 4.3B | 7.5B | 8.0B | 1.1B | 34.7B |
| Income Tax Expense | 186.0M | (266.0M) | (28.0M) | (1.1B) | 3.3B |
| Bottom Line | |||||
| Net Income | 4.0B | 7.8B | 8.0B | 2.1B | 31.4B |
| Earnings from Cont. Ops | 4.1B | 7.8B | 8.1B | 2.2B | 31.4B |
| Earnings from Discont. Ops | (5.0M) | 25.0M | 11.0M | (15.0M) | 6.0M |
| Bottom Line Net Income | 4.0B | 7.8B | 8.0B | 2.1B | 31.4B |
| Per Share | |||||
| Basic EPS | $0.71 | $1.36 | $1.42 | $0.38 | $5.59 |
| Diluted EPS | $0.70 | $1.36 | $1.41 | $0.37 | $5.47 |
| Revenue Per Share | $11.16 | $11.01 | $11.23 | $10.55 | $18.04 |
| Shares | |||||
| Basic Shares Outstanding | 5.7B | 5.7B | 5.7B | 5.6B | 5.6B |
| Diluted Shares Outstanding | 5.8B | 5.7B | 5.7B | 5.7B | 5.7B |
| Profitability Metrics | |||||
| EBITDA | 13.5B | 16.8B | 18.1B | 9.6B | 41.0B |
| D&A | 6.5B | 6.6B | 7.0B | 6.3B | 5.1B |
| EBIT | 7.0B | 10.2B | 11.1B | 3.3B | 36.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026